Effect of Ebola Progression on Transmission and Control in Liberia

被引:62
作者
Yamin, Dan [1 ]
Gertler, Shai [1 ]
Ndeffo-Mbah, Martial L. [1 ]
Skrip, Laura A. [1 ]
Fallah, Mosoka [2 ]
Nyenswah, Tolbert G. [2 ]
Altice, Frederick L. [3 ]
Galvani, Alison P. [1 ]
机构
[1] Yale Univ, Sch Publ Hlth, New Haven, CT 06510 USA
[2] Minist Hlth & Social Welf, Monrovia 1000 10, Liberia
[3] Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT 06510 USA
基金
美国国家卫生研究院;
关键词
HEMORRHAGIC-FEVER; WEST-AFRICA; VIRAL LOAD; RESPONSES; DYNAMICS; OUTBREAK; CONGO; RISK;
D O I
10.7326/M14-2255
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Ebola outbreak that is sweeping across West Africa is the largest, most volatile, and deadliest Ebola epidemic ever recorded. Liberia is the most profoundly affected country, with more than 3500 infections and 2000 deaths recorded in the past 3 months. Objective: To evaluate the contribution of disease progression and case fatality on transmission and to examine the potential for targeted interventions to eliminate the disease. Design: Stochastic transmission model that integrates epidemiologic and clinical data on incidence and case fatality, daily viral load among survivors and nonsurvivors evaluated on the basis of the 2000-2001 outbreak in Uganda, and primary data on contacts of patients with Ebola in Liberia. Setting: Montserrado County, Liberia, July to September 2014. Measurements: Ebola incidence and case-fatality records from 2014 Liberian Ministry of Health and Social Welfare. Results: The average number of secondary infections generated throughout the entire infectious period of a single infected case, R, was estimated as 1.73 (95% CI, 1.66 to 1.83). There was substantial stratification between survivors (R-Survivors), for whom the estimate was 0.66 (CI, 0.10 to 1.69), and nonsurvivors (R-Nonsurvivors), for whom the estimate was 2.36 (CI, 1.72 to 2.80). The nonsurvivors had the highest risk for transmitting the virus later in the course of disease progression. Consequently, the isolation of 75% of infected individuals in critical condition within 4 days from symptom onset has a high chance of eliminating the disease. Limitation: Projections are based on the initial dynamics of the epidemic, which may change as the outbreak and interventions evolve. Conclusion: These results underscore the importance of isolating the most severely ill patients with Ebola within the first few days of their symptomatic phase.
引用
收藏
页码:11 / U140
页数:8
相关论文
共 32 条
[1]  
ANDERSON R M, 1991
[2]  
[Anonymous], 2014, Ebola response roadmap
[3]  
[Anonymous], EBOLA OUTBREAK IN WE
[4]  
[Anonymous], 2014, PLoS Curr. Outbreaks
[5]   Ebola Virus Disease in West Africa - The First 9 Months of the Epidemic and Forward Projections [J].
Aylward, Bruce ;
Barboza, Philippe ;
Bawo, Luke ;
Bertherat, Eric ;
Bilivogui, Pepe ;
Blake, Isobel ;
Brennan, Rick ;
Briand, Sylvie ;
Chakauya, Jethro Magwati ;
Chitala, Kennedy ;
Conteh, Roland M. ;
Cori, Anne ;
Croisier, Alice ;
Dangou, Jean-Marie ;
Diallo, Boubacar ;
Donnelly, Christl A. ;
Dye, Christopher ;
Eckmanns, Tim ;
Ferguson, Neil M. ;
Formenty, Pierre ;
Fuhrer, Caroline ;
Fukuda, Keiji ;
Garske, Tini ;
Gasasira, Alex ;
Gbanyan, Stephen ;
Graaff, Peter ;
Heleze, Emmanuel ;
Jambai, Amara ;
Jombart, Thibaut ;
Kasolo, Francis ;
Kadiobo, Albert Mbule ;
Keita, Sakoba ;
Kertesz, Daniel ;
Kone, Moussa ;
Lane, Chris ;
Markoff, Jered ;
Massaquoi, Moses ;
Mills, Harriet ;
Mulba, John Mike ;
Musa, Emmanuel ;
Myhre, Joel ;
Nasidi, Abdusalam ;
Nilles, Eric ;
Nouvellet, Pierre ;
Nshimirimana, Deo ;
Nuttall, Isabelle ;
Nyenswah, Tolbert ;
Olu, Olushayo ;
Pendergast, Scott ;
Perea, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16) :1481-1495
[6]   Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients [J].
Baize, S ;
Leroy, EM ;
Georges-Courbot, MC ;
Capron, M ;
Lansoud-Soukate, J ;
Debré, P ;
Fisher-Hoch, SP ;
McCormick, JB ;
McCormick, JB ;
Georges, AJ .
NATURE MEDICINE, 1999, 5 (04) :423-426
[7]   Inflammatory responses in Ebola virus-infected patients [J].
Baize, S ;
Leroy, EM ;
Georges, AJ ;
Georges-Courbot, MC ;
Capron, M ;
Bedjabaga, I ;
Lansoud-Soukate, J ;
Mavoungou, E .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 128 (01) :163-168
[8]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[9]   Social Factors in Epidemiology [J].
Bauch, Chris T. ;
Galvani, Alison P. .
SCIENCE, 2013, 342 (6154) :47-49
[10]   Assessment of the risk of Ebola virus transmission from bodily fluids and fomites [J].
Bausch, Daniel G. ;
Towner, Jonathan S. ;
Dowell, Scott F. ;
Kaducu, Felix ;
Lukwiya, Matthew ;
Sanchez, Anthony ;
Nichol, Stuart T. ;
Ksiazek, Thomas G. ;
Rollin, Pierre E. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 196 :S142-S147